Recall: Taytulla Birth Control Capsules
On 2018-05-29, the FDA announced that Allergan is conducting a recall on Birth Control Capsules due to a possible undetermined hazard. The recalled products were sold under the brand name(s) Taytulla during an unspecified time period throughout the regions shown in the map below.
In recent months, there have been 1 drugs recalls due to potential undetermined hazard, including acyclovir tablet, usp, 400mg, 50ct unit dose, intralipid 20% iv fat emulsion, 100 ml and more. Additionally, there have been 29 drug and medical device recalls due to other health hazards as well as 100 food recalls.
Company Contact Information:
Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.
Detailed Recall Information
Regions Where Sold: Because the region was not specified, it is assumed that this product was available nationwide.
Product Description: Birth control capsules
Brand Name(s): Taytulla
Reason for Recall: Undetermined Hazard
Official Recall Date: 2018-05-29
Additional information provided by the FDA.gov:
Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. Read More.
More information may be available at FDA.gov
Latest Safety Recalls
Select image for details, including additional styles.
Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.